Diarylthiohydantoin Synthesis via Segmented Modular Process
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for metastatic prostate cancer, particularly in the castration-resistant state, are ineffective due to the overexpression of the androgen receptor, leading to aggressive disease progression and limited survival options, as therapies intended to block the androgen receptor can sometimes stimulate cancer growth.
Innovation Solution
A novel process for synthesizing diarylthiohydantoin compounds that efficiently inhibit the androgen receptor, using a method that increases overall yield, reduces production time, and avoids toxic reagents, thereby providing a safer and more effective treatment for castration-resistant prostate cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-androgen therapies are used to block the androgen receptor, then hormone-sensitive prostate cancer is treated, but the therapy becomes ineffective and may stimulate growth in castration-resistant prostate cancer
Solution Approach 1:
The patent applies inversion by developing compounds that bind to the androgen receptor in a fundamentally different mode than traditional anti-androgens. Instead of competing with androgens for the same binding site, these compounds induce receptor degradation through a ubiquitin-proteasome pathway, effectively reversing the therapeutic mechanism to overcome resistance.
Solution Approach 2:
The patent changes the therapeutic parameter from receptor blockade to receptor degradation. By modifying the mechanism of action from preventing androgen binding to inducing receptor breakdown, the therapy remains effective against castration-resistant prostate cancer where traditional blockers fail.
2Ease of manufacture
If traditional synthesis processes are used for diarylthiohydantoin compounds, then production can proceed with existing methods, but the overall yield is low and production time is extended
Solution Approach 1:
The patent segments the synthesis into distinct modular steps with isolated purification stages. By dividing the multi-step synthesis process into separate reactions that can be independently optimized and purified, the overall yield increases while maintaining ease of manufacture through standardized operational procedures.
Solution Approach 2:
The patent employs preliminary protection group strategies and pre-formed intermediates to prevent side reactions and simplify subsequent steps. This preliminary preparation of compounds with protected functional groups enables higher overall yields by preventing degradation and side reactions during the synthesis sequence.
3Ease of manufacture
If traditional synthesis processes are used for diarylthiohydantoin compounds, then existing procedures can be followed, but production time is extended due to laborious purification steps
Solution Approach 1:
The patent extracts the purification step from the synthesis sequence by designing reactions that produce products with inherent solubility differences or crystallization properties. This allows direct isolation of pure product without time-consuming column chromatography, reducing production time while maintaining ease of manufacture through simple filtration or crystallization.
Solution Approach 2:
The patent employs self-purification mechanisms where the reaction conditions themselves facilitate product isolation. By designing reactions that produce precipitates, oils, or crystalline products directly in the reaction mixture, the process eliminates separate purification steps and reduces overall production time.
4Productivity
If acetone cyanohydrin is used as a reagent, then the synthesis can proceed, but extreme toxicity creates safety hazards and environmental impact
Solution Approach 1:
The patent converts the harmful acetone cyanohydrin reagent into a beneficial alternative by using compounds that generate the same reactive intermediate in situ under milder, safer conditions. This replaces the toxic reagent with safer alternatives that achieve the same synthetic transformation without the associated toxicity and environmental hazards.
Solution Approach 2:
The patent introduces a safer intermediary reagent that mediates the same chemical transformation without the toxicity of acetone cyanohydrin. By using alternative reagents that produce the same reactive species through different mechanisms, the synthesis maintains productivity while eliminating the harmful factors.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new synthesis process results in a higher yield and safer production of diarylthiohydantoin compounds, effectively inhibiting the androgen receptor, offering a more effective treatment option for castration-resistant prostate cancer by enhancing treatment efficacy and reducing environmental impact.
Implementation Method 1
coupling of an isothiocyanate with an isobutyronitrile
Implementation Method 2
reacting the compound of formula C with a compound of formula R6D
Implementation Method 3
diarylthiohydantoin compounds that efficiently inhibit the androgen receptor
Data Source
AI summary
Processes are provided for the synthesis of diarylthiohydantoin and diarylhydantoin compounds, such as compounds of the formula: wherein X, Y1, Y2, R1, and R2 are as defined herein. Medicinal products containing the same find particular use in treating prostate cancer, including castration-resistant prostate cancer and/or hormone-sensitive prostate cancer.